Figure 3

Metastatic neuroblastoma variants are more resistant than local variants to growth inhibition mediated by the HK2 inhibitor 3-BrPa. (A) Viability of local and metastatic neuroblastoma variants was determined by XTT-based viability assays following treatment with 25, 50 and 100 μ M 3-BrPa. (B) The activity of all HK isoforms in neuroblastoma variants was determined following treatment with 50 μ M 3-BrPa by measuring microunit enzyme per ml (μU ml⁻¹) normalised to control untreated cells. Data are means of three independent experiments+s.d. Significance was evaluated using Student’s t-test. *P<0.05, **P<0.01, ***P<0.005 and ****P<0.001.